A B S T R A C T Type V hyperlipoproteinemia (HLP) is characterized clinically by hepatosplenomegaly, occasional eruptive xanthomas, and an increased incidence of pancreatitis. These patients have striking hypertriglyceridemia due to increased plasma chylomicron and very low density lipoprotein concentrations in the fasting state, without a deficiency of lipoprotein lipase or its activator protein, apolipoprotein (apo) C-II. ApoE, a protein constituent of triglyceride-rich lipoproteins, has been implicated in the receptor-mediated hepatic uptake of these particles. ApoE has three major alleles: E2, E3, and E4, and the products of these alleles are apoE2, apoE3, and apoE4, respectively. ApoE phenotypes were determined in 30 type V HLP patients as well as in 37 normal volunteers. Among the type V patients, 33.3% were noted to be homozygous, and 40.0% heterozygous for E4 (normal, 2.7 and 21.6%, respectively). These data suggest that apoE4 may play a role in the etiology of the hyperlipidemia in a significant number of type V HLP patients.
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INTRODUCTION
Apolipoprotein (apo) E is a major protein constituent of plasma very low density lipoproteins (VLDL)l (1, 2) . Studies in animals and man indicate that apoE may play a crucial role in the regulation of lipoprotein metabolism and is possibly involved in the atherogenic process (3). ApoE has been reported to be important in the receptor-mediated uptake by the liver of tri- glyceride-rich lipoproteins, especially chylomicron remnants (4) (5) (6) . Isoelectrofocusing (IEF) of delipidated VLDL protein by polyacrylamide gel electrophoresis (PAGE) demonstrates the presence of three major apoE bands in man: E2, E3, and E4 (7, 8) . These apoE bands differ in their isoelectric point due to arginine for cysteine substitutions at two positions in the polypeptide chain (9) .
ApoE has been proposed to be inherited at a single genetic locus with three common alleles (8 (12) . Plasma apoE concentrations have been shown to be increased in most patients with type III HLP and type V HLP (13) (14) (15) (16) . Type V patients may have hepatosplenomegaly, lipemia retinalis, eruptive xanthomas, and pancreatitis (17) . These patients have striking hy-2 In this report apoE alleles are designated as E2, E3, and E4, and the gene products of these alleles are apoE2, apoE3, and apoE4, respectively. The six apoE genotypes are E'/E', E3/E3, E4/E4, E2/E3, E2/E4, and E3/E4. The corresponding phenotypes, as determined by IEF PAGE, for homozygotes are E2, E3, and E4, and for heterozygotes E2/3, E2/4, and E3/4, respectively. The major apoE isoforms on IEF PAGE are designated as the E2, E3, and E4 bands. pertriglyceridemia in the fasting state due to elevations of both chylomicrons and VLDL (17) . The purpose of this study was to investigate apoE phenotypes in type V HLP patients. We observed a higher than expected prevalence of E4 homozygosity and heterozygosity, consistent with the concept that apoE4 may play a role in the pathogenesis of type V HLP.
METHODS
30 type V hyperlipoproteinemic patients were selected from the dyslipoproteinemic patients attending the clinic of the Molecular Disease Branch at the National Institutes of Health. The mean age of these patients was 51±8 yr (mean±SD). Subjects were diagnosed as having type V hyperlipoproteinemia by the following criteria: (a) plasma triglyceride above 1,000 mg/dl, (b) chylomicrons and VLDL present in fasting plasma as determined by lipoprotein electrophoresis (18), (c) no evidence of lipoprotein lipase deficiency (19) , and (d) no plasma apoC II deficiency (20) . No patients had secondary causes of hyperlipidemia other than diabetes mellitus (40%) and obesity. Almost all patients were on low fat (20% of calories) diets when sampled for this study, and none were receiving medication known to affect plasma lipids except for diabetic subjects who required insulin. 37 normal subjects were also analyzed for the apoE phenotype. Their mean age was 27±4 yr.
Blood was obtained in 0.1% EDTA after an overnight fast, and the plasma was separated at 4°C in a refrigerated centrifuge. Plasma cholesterol and triglyceride levels were measured with a Technicon Auto Analyzer II (Technicon Instruments Corp., Tarrytown, NY) (18) . VLDL were separated by ultracentrifugation at 1.006 g/ml at 39,000 rpm for 18 h at 4°C in Beckman 40.3 rotors (Beckman Instruments, Inc., Fullerton, CA), and the lipoprotein fractions were recovered by tube slicing (21) . HDL cholesterol was measured after heparin-manganese precipitation of the 1.006 g/ml plasma infranate. Low density lipoprotein (LDL) cholesterol was calculated by subtraction of the HDL cholesterol from the 1.006 g/ml plasma infranate cholesterol value (18) . VLDL, 1.006 g/ml infranate, and HDL cholesterol levels were determined by automated techniques as described for plasma. Lipoprotein electrophoresis for lipoprotein phenotyping was performed on the plasma and the 1.006-g/ml supernate and infranate (18) .
VLDL were isolated by ultracentrifugation as previously described and washed a second time by the same technique.
The isolated lipoproteins were desalted by passage through a Sephadex G-25 prepacked column (Pharmacia AB, Uppsala, Sweden) (6 X 1.5 cm), equilibrated, and eluted with 0.08% ammonium bicarbonate. VLDL Utermann et al. (7) ; 2 to that used by Zannis and Breslow (8) , and 3 refers to the nomenclature used in this report. t Phenotype frequencies for the population 1 have been calculated from the data presented by Utermann et al. (7) for a normal population studied in Germany. Phenotype frequencies for normal population 2 have been reported by Zannis and Breslow (8) . Normal population 3 is that analyzed in this study.
§ Normal population. The number of the subjects studied is given in parentheses.
accumulation of chylomicron remnants containing apoB-48 and apoA-IV within VLDL, IDL, and LDL density fractions (12) . Lipoproteins containing apoE2 have a reduced uptake by the perfused rat liver (6) and have a delayed clearance in man when compared with lipoproteins containing apoE3 (11) . These data indicate that the apoE and its isoforms may be of important clinical significance and may affect the catabolism of the triglyceride-rich lipoproteins in man. Our results are consistent with the concept that the presence of the E4 allele may be a genetic factor that predisposes or contributes to the development of type V HLP. A much higher frequency of this apoE phenotype was observed in the type V HLP patients studied than that noted in normal populations (7, 8, 10) . However, only a portion of the patients studied had this phenotype. This suggests that type V HLP may be due to several different molecular defects. The data presented in this report indicate that one form of apoE (apoE4) may be important in the pathogenesis of type V HLP.
